Literature DB >> 19951061

Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme.

Pantaleo Romanelli1, Alfredo Conti, Antonio Pontoriero, Giuseppe Kenneth Ricciardi, Francesco Tomasello, Costantino De Renzis, Gualtiero Innocenzi, Vincenzo Esposito, Giampaolo Cantore.   

Abstract

Glioblastoma multiforme (GBM) is a devastating malignant brain tumor characterized by resistance to available therapeutic approaches and relentless malignant progression that includes widespread intracranial invasion, destruction of normal brain tissue, progressive disability, and death. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) are increasingly used in patients with recurrent GBM to complement traditional treatments such as resection, conventional external beam radiotherapy, and chemotherapy. Both SRS and fSRT are powerful noninvasive therapeutic modalities well suited to treat focal neoplastic lesions through the delivery of precise, highdose radiation. Although no randomized clinical trials have been performed, a variety of retrospective studies have been focused on the use of SRS and fSRT for recurrent GBMs. In addition, state-of-the-art neuroimaging techniques, such as MR spectroscopic imaging, diffusion tensor tractography, and nuclear medicine imaging, have enhanced treatment planning methods leading to potentially improved clinical outcomes. In this paper the authors reviewed the current applications and efficacy of SRS and fSRT in the treatment of GBM, highlighting the value of these therapies for recurrent focal disease.

Entities:  

Mesh:

Year:  2009        PMID: 19951061     DOI: 10.3171/2009.9.FOCUS09187

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  27 in total

1.  Prognostic factors in patients treated with stereotactic image-guided robotic radiosurgery for brain metastases: a single-center retrospective analysis of 223 patients.

Authors:  Antonio Pontoriero; Alfredo Conti; Giuseppe Iatì; Stefania Mondello; Dario Aiello; Carmen Rifatto; Edoarda Risoleti; Micol Mazzei; Francesco Tomasello; Stefano Pergolizzi; Costantino De Renzis
Journal:  Neurosurg Rev       Date:  2016-04-23       Impact factor: 3.042

2.  Effect of hyperoxygenation on tissue pO2 and its effect on radiotherapeutic efficacy of orthotopic F98 gliomas.

Authors:  Nadeem Khan; Sriram Mupparaju; Shahryar K Hekmatyar; Huagang Hou; Jean P Lariviere; Eugene Demidenko; David J Gladstone; Risto A Kauppinen; Harold M Swartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-31       Impact factor: 7.038

Review 3.  Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.

Authors:  Sarah J Nelson
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

4.  RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.

Authors:  Ann C Mladek; Huihuang Yan; Shulan Tian; Paul A Decker; Danielle M Burgenske; Katrina Bakken; Zeng Hu; Lihong He; Margaret A Connors; Brett L Carlson; Jonathan Wilson; Archana Bommi-Reddy; Andy Conery; Jeanette E Eckel-Passow; Jann N Sarkaria; Gaspar J Kitange
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

5.  American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS).

Authors:  Steven K Seung; David A Larson; James M Galvin; Minesh P Mehta; Louis Potters; Christopher J Schultz; Santosh V Yajnik; Alan C Hartford; Seth A Rosenthal
Journal:  Am J Clin Oncol       Date:  2013-06       Impact factor: 2.339

6.  MRI tumor response and clinical outcomes after LINAC radiosurgery on 50 patients with recurrent malignant gliomas.

Authors:  Toufic Khalil; Jean Jacques Lemaire; Véronique Dedieu; Denise Donnarieix; Claise Béatrice; Michel Lapeyre; Jean Louis Kemeny; Bruno Pereira; Aurélie Thalami; Jean Chazal; Pierre Verrelle
Journal:  J Radiosurg SBRT       Date:  2013

7.  Dosimetric comparison of Gamma Knife® IconTM and linear accelerator-based fractionated stereotactic radiotherapy (FSRT) plans for the re-irradiation of large (>14 cm3) recurrent glioblastomas.

Authors:  Matthew E Schelin; Haisong Liu; Ayesha Ali; Wenyin Shi; Yan Yu; Karen E Mooney
Journal:  J Radiosurg SBRT       Date:  2021

8.  Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.

Authors:  Sudheer R Thumma; Robert K Fairbanks; Wayne T Lamoreaux; Alexander R Mackay; John J Demakas; Barton S Cooke; Ameer L Elaimy; Peter W Hanson; Christopher M Lee
Journal:  World J Surg Oncol       Date:  2012-05-03       Impact factor: 2.754

9.  Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma.

Authors:  M Rivera; Q Wu; P Hamerlik; A B Hjelmeland; S Bao; J N Rich
Journal:  Cell Death Dis       Date:  2015-04-23       Impact factor: 8.469

10.  Predicting brain tumor regrowth in relation to motor areas by functional brain mapping.

Authors:  Nico Sollmann; Tobias Laub; Anna Kelm; Lucia Albers; Jan S Kirschke; Stephanie E Combs; Bernhard Meyer; Sandro M Krieg
Journal:  Neurooncol Pract       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.